Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

onchocerciasis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

onchocerciasis

MONDO:0017137

Also known as:Onchocerca volvulus infectioninfection by Onchocerca volvulusvolvulosis

Find Clinical TrialsTrials

Overview

Onchocerciasis is a form of filariasis, caused by the parasitic worm Onchocerca volvulus, transmitted by the black fly. The infection can either be asymptomatic or manifest as an ocular disease (river blindness) with itchy eyes, erythema, photophobia, onchodermatitis or onchocercal skin disease (classified into acute papular, chronic papular, lichenified, atrophic, and depigmentated) and onchocercomas (over bony prominences). Other classic clinical manifestations are ichthyosis-like lesions (''lizard skin'') and ''hanging groin'', which may be associated with lymphadenopathy.

Treatments1 FDA approved

Clinical Trials9 registered · 4 recruiting

Diagnosis

Biomarker and diagnostic research for onchocerciasis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for onchocerciasis, including MOXIDECTIN (MOXIDECTIN, approved 2018). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

9 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and biologic therapy. Pipeline includes 1 PHASE4, 1 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06070116](https://clinicaltrials.gov/study/NCT06070116)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:58 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:2737

GARD

Genetic and Rare Diseases Info Center

GARD:7252

Questions for Your Care Team

→What are the benefits and potential side effects of MOXIDECTIN for managing onchocerciasis?
→Are any of the 9 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
4¿-(p-fluorobenzyl)tylosin A	4¿-(p-fluorobenzyl)tylosin A	AbbVie Inc.	2017	—	Withdrawn
flubendazole	flubendazole	Janssen Research & Development, LLC	2013	—	Withdrawn

Research Type	Count	% of Total
Research summaries	22	43%
Disease patterns and progression	22	43%
Clinical study results	3	6%
Testing and diagnosis research	2	4%
Other research	1	2%
Laboratory research	1	2%

Kisho

onchocerciasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Intravitreal Onchocerca sp. With Concomitant Cerebral MRI Lesion: A Case Report.

onchocerciasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Intravitreal Onchocerca sp. With Concomitant Cerebral MRI Lesion: A Case Report.